half life

Summary

Summary: The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.

Top Publications

  1. pmc Global analysis of mRNA decay and abundance in Escherichia coli at single-gene resolution using two-color fluorescent DNA microarrays
    Jonathan A Bernstein
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 99:9697-702. 2002
  2. ncbi Superior serum half life of albumin tagged TNF ligands
    Nicole Muller
    Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Wurzburg, Rontgenring 11, 97070 Wurzburg, Germany
    Biochem Biophys Res Commun 396:793-9. 2010
  3. ncbi Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer
    Rene Bruno
    Pharmacokinetic and Pharmacodynamic Sciences, MS 70 Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 56:361-9. 2005
  4. pmc Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes
    Edward Yang
    Laboratory of Molecular Cell Biology, The Rockefeller University, New York, New York 10021 6399, USA
    Genome Res 13:1863-72. 2003
  5. ncbi Generation of destabilized green fluorescent protein as a transcription reporter
    X Li
    Laboratories, Inc, Palo Alto, California 94303, USA
    J Biol Chem 273:34970-5. 1998
  6. pmc Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination
    O Staub
    Hospital for Sick Children, Division of Respiratory Research, Toronto, Ontario, Canada
    EMBO J 16:6325-36. 1997
  7. pmc Quantification of protein half-lives in the budding yeast proteome
    Archana Belle
    Department of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California, San Francisco, 94143 2240, USA
    Proc Natl Acad Sci U S A 103:13004-9. 2006
  8. pmc Genome-wide analysis of mRNA decay rates and their determinants in Arabidopsis thaliana
    Reena Narsai
    Australian Research Council Centre of Excellence in Plant Energy Biology, University of Western Australia, Crawley 6009, Australia
    Plant Cell 19:3418-36. 2007
  9. ncbi Selenium: a key element that controls NF-kappa B activation and I kappa B alpha half life
    C Kretz-Remy
    CNRS-UMR 5534, , Bat. Gregor Mendel, 16 rue Dubois, , France
    Biofactors 14:117-25. 2001
  10. ncbi Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats
    A M Abd El-Aty
    Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, 12515 Giza, Egypt
    Pharmacol Res 49:487-91. 2004

Detail Information

Publications229 found, 100 shown here

  1. pmc Global analysis of mRNA decay and abundance in Escherichia coli at single-gene resolution using two-color fluorescent DNA microarrays
    Jonathan A Bernstein
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 99:9697-702. 2002
    ..Our results identify previously unsuspected features of mRNA decay at a global level and also indicate that generalizations about decay derived from the study of individual gene transcripts may have limited applicability...
  2. ncbi Superior serum half life of albumin tagged TNF ligands
    Nicole Muller
    Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Wurzburg, Rontgenring 11, 97070 Wurzburg, Germany
    Biochem Biophys Res Commun 396:793-9. 2010
    ..To improve the serum half life of the TNF family members TNF, TWEAK and TRAIL, we genetically fused soluble variants of these molecules to ..
  3. ncbi Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer
    Rene Bruno
    Pharmacokinetic and Pharmacodynamic Sciences, MS 70 Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Cancer Chemother Pharmacol 56:361-9. 2005
    ..To characterize the population pharmacokinetics of trastuzumab in patients with metastatic breast cancer...
  4. pmc Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes
    Edward Yang
    Laboratory of Molecular Cell Biology, The Rockefeller University, New York, New York 10021 6399, USA
    Genome Res 13:1863-72. 2003
    ....
  5. ncbi Generation of destabilized green fluorescent protein as a transcription reporter
    X Li
    Laboratories, Inc, Palo Alto, California 94303, USA
    J Biol Chem 273:34970-5. 1998
    ..Because of its autofluorescence, destabilized EGFP can be used to directly correlate gene induction with biochemical change, such as NFkappaB translocation to the nucleus...
  6. pmc Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination
    O Staub
    Hospital for Sick Children, Division of Respiratory Research, Toronto, Ontario, Canada
    EMBO J 16:6325-36. 1997
    ..Our results suggest that ENaC function is regulated by ubiquitination, and propose a paradigm for ubiquitination-mediated regulation of ion channels...
  7. pmc Quantification of protein half-lives in the budding yeast proteome
    Archana Belle
    Department of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California, San Francisco, 94143 2240, USA
    Proc Natl Acad Sci U S A 103:13004-9. 2006
    ..Our experimental data and theoretical analysis underscore the importance of an integrative approach to the complex interplay between protein degradation, transcriptional regulation, and other determinants of protein metabolism...
  8. pmc Genome-wide analysis of mRNA decay rates and their determinants in Arabidopsis thaliana
    Reena Narsai
    Australian Research Council Centre of Excellence in Plant Energy Biology, University of Western Australia, Crawley 6009, Australia
    Plant Cell 19:3418-36. 2007
    ....
  9. ncbi Selenium: a key element that controls NF-kappa B activation and I kappa B alpha half life
    C Kretz-Remy
    CNRS-UMR 5534, , Bat. Gregor Mendel, 16 rue Dubois, , France
    Biofactors 14:117-25. 2001
    ..These results suggest that selenium is a key element that through its modulation of glutathione peroxidase activity can inhibit NF-kappa B activation and can up-regulate I kappa B alpha normal half life.
  10. ncbi Pharmacokinetics of doxycycline after administration as a single intravenous bolus and intramuscular doses to non-lactating Egyptian goats
    A M Abd El-Aty
    Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, 12515 Giza, Egypt
    Pharmacol Res 49:487-91. 2004
    ..The extent of serum protein binding percent was 32.8% and the systemic bioavailability was 99.40% after i.m. injection of 5 mg kg-1 BW..
  11. ncbi Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
    M Tsiang
    Gilead Sciences, Foster City, CA, USA
    Hepatology 29:1863-9. 1999
    ..These quantitative analyses provide a more detailed picture of the dynamics of HBV infection and therapy, and can be used to compare the efficacy of various doses and inhibitors of HBV replication for the treatment of HBV infections...
  12. pmc Global analysis of mRNA decay in Halobacterium salinarum NRC-1 at single-gene resolution using DNA microarrays
    Sonja Hundt
    Institut fur Mikrobiologie und Molekularbiologie, Justus Liebig Universitat, Heinrich Buff Ring 26 32, D 35392 Giessen, Germany
    J Bacteriol 189:6936-44. 2007
    ..This complex orthologous to the RNA degrading exosome of eukarya is found in all other archaeal genomes sequenced thus far...
  13. pmc Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn
    E J Israel
    Combined Program in Pediatric Gastroenterology and Nutrition, Harvard Medical School, Massachusetts General Hospital, Boston, USA
    Immunology 89:573-8. 1996
    ..These data suggest that FcRn can protect IgG from degradation, and is therefore important in maintaining IgG levels in the circulation...
  14. ncbi Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice
    V Ghetie
    Department of Microbiology, University of Texas Southwestern Medical Center, Dallas 75235 8576, USA
    Eur J Immunol 26:690-6. 1996
    ..These findings suggest that FcRn is involved in IgG homeostasis...
  15. pmc Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells
    A Hengstermann
    Institute of Biochemistry I, Medical Faculty, University of Cologne, Joseph-Stelzmann-Strasse 52, , Germany
    Proc Natl Acad Sci U S A 98:1218-23. 2001
    ....
  16. ncbi Pharmacokinetics and tissue distribution of doxycycline after oral administration of single and multiple doses in horses
    Jennifer L Davis
    Clinical Pharmacology, Research Laboratories, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA
    Am J Vet Res 67:310-6. 2006
    ..To determine pharmacokinetics, safety, and penetration into interstitial fluid (ISF), polymorphonuclear leukocytes (PMNLs), and aqueous humor of doxycycline after oral administration of single and multiple doses in horses...
  17. ncbi Effective half life of iodine for five thyroidectomy patients using an in vivo gamma camera approach
    Chien Yi Chen
    Department of Medical Imaging and Radiology Science Chung Shan Medical University, Taichung, Taiwan
    J Radiat Res 48:485-93. 2007
    ..However, this dominant compartment was shifted to both thyroid and body fluid, based on analyses of the data following thyroidectomy, for the patients herein...
  18. ncbi Pharmacokinetics and bioavailability of doxycycline in fasted and nonfasted broiler chickens
    P Laczay
    Department of Pharmacology and Toxicology, Faculty of Veterinary Science, Szent Istvan University, H 1400 Budapest, P O Box 2, Hungary
    Acta Vet Hung 49:31-7. 2001
    ..5%. The presence of food in the intestinal tract reduced and extended the absorption (t1/2a = 1.23 +/- 0.21 h; Cmax = 3.07 +/- 0.23 micrograms/mL; tmax = 3.34 +/- 0.21 h). The absolute bioavailability was reduced to 61.1% +/- 4.4%...
  19. ncbi Strategies to improve plasma half life time of peptide and protein drugs
    M Werle
    ThioMatrix GmbH, Research Center Innsbruck, Innsbruck, Austria
    Amino Acids 30:351-67. 2006
    Due to the obvious advantages of long-acting peptide and protein drugs, strategies to prolong plasma half life time of such compounds are highly on demand...
  20. pmc Individual gvp transcript segments in Haloferax mediterranei exhibit varying half-lives, which are differentially affected by salt concentration and growth phase
    Andreas Jager
    Institut fur Mikrobiologie und Molekularbiologie, Justus Liebig Universitat Giessen, Heinrich Buff Ring 26, D 35392 Giessen, Germany
    Nucleic Acids Res 30:5436-43. 2002
    ..This implies that, like in bacteria and eukarya, mRNA processing contributes to regulated gene expression in archaea...
  21. ncbi Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding
    Xingrong Liu
    Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Groton, CT 06340, USA
    J Pharmacol Exp Ther 313:1254-62. 2005
    ..The strategy to select compounds with rapid brain equilibration in drug discovery should identify compounds with high BBB permeability and low nonspecific binding in brain tissue...
  22. pmc Global analysis of Escherichia coli RNA degradosome function using DNA microarrays
    Jonathan A Bernstein
    Department of Genetics, Stanford University, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 101:2758-63. 2004
    ....
  23. pmc Photodynamic therapy effect of m-THPC (Foscan) in vivo: correlation with pharmacokinetics
    H J Jones
    DI Vernon School of Biochemistry and Molecular Biology, Centre for Photobiology and Photodynamic Therapy, University of Leeds, Leeds LS2 9JT, UK
    Br J Cancer 89:398-404. 2003
    ..These results indicate that the in vivo PDT effect of m-THPC occurs via several mechanisms...
  24. ncbi Formulation-dependent toxicokinetics explains differences in the GI absorption, bioavailability and acute neurotoxicity of deltamethrin in rats
    Kyu Bong Kim
    Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30605, USA
    Toxicology 234:194-202. 2007
    ..In summary, limited dissolution of the highly lipophilic DLM particles in the AL suspension severely limited DLM's GI absorption, bioavailability, target organ deposition and acute neurotoxic potency...
  25. ncbi Laronidase treatment of mucopolysaccharidosis I
    Ed J Wraith
    Willink Biochemical Genetics Unit, Royal Manchester Children s Hospital, Manchester, UK
    BioDrugs 19:1-7. 2005
    ....
  26. pmc Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner
    Dipankar Ray
    Department of Biochemistry and Molecular Genetics, University of Illinois College of Medicine, Chicago, IL 60607, USA
    Mol Cell Biol 25:3338-47. 2005
    ..These data suggest that Smad3 plays a key role in the regulation of Cdc25A ubiquitination by SCFbeta-TrCP and that Cdc25A stabilization observed in various cancers could be associated with defects in the TGF-beta-Smad3 pathway...
  27. ncbi Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A
    Sean X Peng
    Johnson and Johnson Pharmaceutical Research and Development, 1000 Route 202, Raritan, New Jersey 08869, USA
    J Pharm Sci 95:1984-93. 2006
    ..The enhanced oral absorption by BA coadministration may be exploited to improve oral bioavailability of Pgp and CYP3A substrate compounds...
  28. ncbi Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans
    Richard E Ostlund
    Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine, Missouri 63017, USA
    Am J Physiol Endocrinol Metab 282:E911-6. 2002
    ..We conclude that the efficiency of phytosterol absorption is lower than what was reported previously and is critically dependent on the structure of both sterol nucleus and side chain...
  29. pmc Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD
    Claude Emond
    National Research Council, National Academy of Sciences, Washington, DC, USA
    Environ Health Perspect 114:1394-400. 2006
    ..This demonstrates that an inducible elimination rate is needed in a PBPK model in order to describe the pharmacokinetics of TCDD. At low exposures these models are more sensitive to parameters related to partitioning into adipose tissue...
  30. pmc Gene set coregulated by the Saccharomyces cerevisiae nonsense-mediated mRNA decay pathway
    Rachel Taylor
    School of Biological Sciences, University of Nebraska Lincoln, NE 68588 0666, USA
    Eukaryot Cell 4:2066-77. 2005
    ..This strategy is significant because it allows us to classify the genes regulated by NMD into functionally related sets, an important step toward understanding the role NMD plays in the normal functioning of yeast cells...
  31. doi Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells
    Wendy W Batenburg
    Erasmus MC, 3015 GE Rotterdam, The Netherlands
    Arterioscler Thromb Vasc Biol 28:1151-7. 2008
    ..We also investigated whether aliskiren affects (pro)renin binding to its receptors, using rat aortic vascular smooth muscle cells (VSMCs) overexpressing the h(P)RR...
  32. ncbi Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids
    F Shojaee Aliabadi
    Department of Veterinary Basic Sciences, The Royal Veterinary College, Hawkshead Campus, North Mymms, Hatfield AL9 7TA, Hertfordshire, UK
    Vet J 165:104-18. 2003
    ....
  33. ncbi Alteration of pharmacokinetics of oxytetracycline following oral administration of Piper longum in hens
    M Singh
    Department of Pharmacology and Toxicology, College of Veterinary and Animal Sciences, CSK Himachal Pradesh Agricultural University, Himachal Pradesh, India
    J Vet Sci 6:197-200. 2005
    ..Prior treatment of P.longum significantly reduced elimination rate constant(beta)and increased elimination half life (t(1/2beta))...
  34. ncbi Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys--probing the determinants of long plasma half-lives
    Melvin E Andersen
    CIIT Centers for Health Research, Research Triangle Park, NC 27709 2137, United States
    Toxicology 227:156-64. 2006
    ..PFOS has longer half-life and had respective values of 13.6 mg/(h kg), 0.023 mg/L, and 0.025. PFOS appeared to have a higher transport capacity and lower affinity than PFOA. Human kinetics indicates even higher resorption efficiency...
  35. ncbi Quantitative liver function tests in donors and recipients of living donor liver transplantation
    Christoph Jochum
    Department of Gastroenterology and Hepatology, University Hospital Essen, University Duisburg Essen, Essen, Germany
    Liver Transpl 12:544-9. 2006
    ..The donors had better test results and recovered faster than the recipients. In conclusion, after LDLT the parameters for liver capacity and flow remain altered in donors and recipients despite rapid volume growth...
  36. pmc Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and oral administration in pigs
    Zhi Qiang Chang
    College of Veterinary Medicine, Kyungpook National University, Daegu 702 701, Korea
    J Vet Sci 8:353-6. 2007
    ..The mean systemic bioavailability (F) after p.o. administration was 31.10 +/- 15.16%. We suggest that the optimal dosage calculated from the pharmacokinetic parameters is 5.01 mg/kg per day i.v. or 16.12 mg/kg per day p.o...
  37. pmc Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes
    Arvind Raghavan
    Department of Microbiology, University of Minnesota, Minneapolis, MN 55455, USA
    Nucleic Acids Res 30:5529-38. 2002
    ..Thus, rapid mRNA degradation appears to be an important mechanism for turning gene expression off in an activation-dependent manner...
  38. pmc The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions
    H Le Hir
    Howard Hughes Medical Institute, Department of Biochemistry, Brandeis University, 415 South Street, Waltham, MA 02454, USA
    EMBO J 19:6860-9. 2000
    ..Possible functions for this complex in nucleocytoplasmic transport of spliced mRNA, as well as the nonsense-mediated mRNA decay pathway, are discussed...
  39. pmc Pharmacokinetics, urinary excretion and dosage regimen of levofloxacin following a single intramuscular administration in cross bred calves
    Vinod K Dumka
    Department of Pharmacology and Toxicology, College of Veterinary Science, Guru Angad Dev Veterinary and Animal Science University, Ludhiana 141004, India
    J Vet Sci 7:333-7. 2006
    ..The total body clearance (Cl(B)) was 204.9+/-22.6 ml/kg/h. On the basis of the pharmacokinetic parameters, a suitable intramuscular dosage regimen for levofloxacin in calves would be 1.5 mg/kg repeated at 12 h intervals...
  40. ncbi Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?
    Gary W Caldwell
    Johnson and Johnson Pharmaceutical Research and Development, L L C Drug Discovery, Spring House, PA 19477, USA
    Eur J Drug Metab Pharmacokinet 29:133-43. 2004
    ....
  41. ncbi Sloppy-model universality class and the Vandermonde matrix
    Joshua J Waterfall
    Laboratory of Atomic and Solid State Physics, Cornell University, Ithaca, New York 14853, USA
    Phys Rev Lett 97:150601. 2006
    ..In particular, we motivate focusing on a Vandermonde ensemble of multiparameter nonlinear models and show in one limit that they exhibit the universal features of sloppy models...
  42. ncbi Concentration and age-dependent elimination kinetics of polychlorinated dibenzofurans in Yucheng and Yusho patients
    H W Leung
    Health Science Resource Integration, Tallahassee, Florida 32309, USA
    Toxicol Ind Health 23:493-501. 2007
    ..The current study provides limited additional evidence that PCDFs, like TCDD, are more rapidly eliminated in younger individuals...
  43. pmc Whole-genome analysis of mRNA decay in Plasmodium falciparum reveals a global lengthening of mRNA half-life during the intra-erythrocytic development cycle
    Jennifer L Shock
    Department of Biochemistry and Biophysics, University of California San Francisco, 1700 4th Street, San Francisco, California 94158 2330, USA
    Genome Biol 8:R134. 2007
    ..Previously, studies in several organisms found that the specific half-life of each mRNA is precisely related to its physiologic role, and plays an important role in determining levels of gene expression...
  44. ncbi Factor VIII half-life and clinical phenotype of severe hemophilia A
    Karin van Dijk
    Van Creveldkliniek, UMCU, Room C01 425 PO Box 85500, 3508 GA Utrecht, The Netherlands
    Haematologica 90:494-8. 2005
    ..The aim of this study was to describe the association of factor VIII half-lives with treatment and clinical characteristics of patients with severe hemophilia A, who have been treated with individually tailored prophylaxis...
  45. pmc Global analysis of mRNA stability in the archaeon Sulfolobus
    Anders F Andersson
    Department of Gene Technology, School of Biotechnology, KTH Royal Institute of Technology, AlbaNova University Center, SE 106 91 Stockholm, Sweden
    Genome Biol 7:R99. 2006
    ..Here, we present a microarray-based analysis of mRNA half-lives in the hyperthermophilic crenarchaea Sulfolobus solfataricus and Sulfolobus acidocaldarius, constituting the first genome-wide study of RNA decay in archaea...
  46. pmc Age- and concentration-dependent elimination half-life of 2,3,7,8-tetrachlorodibenzo-p-dioxin in Seveso children
    Brent D Kerger
    Health Science Resource Integration, Tallahassee, Florida, USA
    Environ Health Perspect 114:1596-602. 2006
    ..Pharmacokinetic and statistical analyses are reported to elucidate key variables affecting 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) elimination in children and adolescents...
  47. ncbi Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol
    U I Schwarz
    Medical Faculty, Institute of Clinical Pharmacology, Technical University Dresden, Dresden, Germany
    Clin Pharmacol Ther 81:669-78. 2007
    ..Interestingly, the magnitude of induction appeared to be affected by MDR1 genotype...
  48. ncbi von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis
    A Y Nossent
    Hematology, Hemostasis and Thrombosis Research Center, Leiden University Medical Center, Leiden, The Netherlands
    J Thromb Haemost 4:2556-62. 2006
    ..VWF is secreted in equimolar amounts with its propeptide, which has a shorter half-life. VWF propeptide can be used as a measure of VWF secretion and allows estimation of the VWF half-life...
  49. ncbi Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys
    J L Butenhoff
    3M, St Paul, Minnesota 55144, USA
    Toxicol Sci 82:394-406. 2004
    ..Based on the result of both the oral and iv studies, the elimination half-life is approximately 14-42 days, and urine is the primary route of excretion...
  50. ncbi Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa
    Stefan Schulte
    CSL Behring GmbH, Emil von Behring Strasse 76, Marburg, Germany
    Thromb Res 122:S14-9. 2008
    ..These data suggest that rVIIa-FP may be a promising therapy for the treatment of haemophilia patients with inhibitors and warrants further investigation in clinical trials...
  51. ncbi Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs
    Stefan S De Buck
    Johnson and Johnson Pharmaceutical Research and Development, Discovery ADME Tox Department, Beerse, Belgium
    Drug Metab Dispos 35:1766-80. 2007
    ..This evaluation demonstrates that PBPK models can lead to reasonable predictions of human pharmacokinetics...
  52. pmc The evolution of drug-resistant malaria: the role of drug elimination half-life
    Ian M Hastings
    Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
    Philos Trans R Soc Lond B Biol Sci 357:505-19. 2002
    ..The model is also applicable to the evolution of antibiotic resistance in bacteria: in particular, the need for these models to incorporate drug pharmacokinetics to avoid potentially large errors in their predictions...
  53. ncbi Hormonal regulation of cytochrome P450 aromatase mRNA stability in non-luteinizing bovine granulosa cells in vitro
    Malha Sahmi
    Centre de Recherche en Reproduction Animale, Faculte de Medecine Veterinaire, Universite de Montreal, C P 5000, St Hyacinthe, Quebec J2S 7C6, Canada
    J Endocrinol 190:107-15. 2006
    ..05) that in FSH-stimulated cells. We conclude that bovine Cyp19 mRNA is very labile under physiological conditions, and that Cyp19 expression is under hormonal control at a post-transcriptional level...
  54. doi A thermostable triple mutant of pyranose 2-oxidase from Trametes multicolor with improved properties for biotechnological applications
    Oliver Spadiut
    Department of Food Sciences and Technology, BOKU, Vienna, Austria
    Biotechnol J 4:525-34. 2009
    ..The half life time at 60 degrees C was approximately 10 h, compared to 7.6 min for the wild-type enzyme...
  55. ncbi Posttranscriptional derepression of GADD45alpha by genotoxic stress
    Ashish Lal
    Laboratory of Cellular and Molecular Biology, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA
    Mol Cell 22:117-28. 2006
    ..We propose that the posttranscriptional derepression of GADD45alpha critically contributes to its potent upregulation after DNA damage...
  56. ncbi Elimination half-lives of selected polychlorinated dibenzodioxins and dibenzofurans in breast-fed human infants
    Hon Wing Leung
    Health Science Resource Integration, Inc, Tallahassee, Florida, USA
    J Toxicol Environ Health A 69:437-43. 2006
    ..Thus, the shorter half-life of dioxins during breastfeeding needs to be considered when evaluating the dioxin hazard to children...
  57. doi Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects
    J Møss
    Medical and Science, Novo Nordisk A S, Bagsvaerd, Denmark
    J Thromb Haemost 7:299-305. 2009
    ..NN1731 is a recombinant activated factor VII (rFVIIa) analog with enhanced activity...
  58. ncbi Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients
    Xiaoqiang Xiang
    Laboratory of Clinical Pharmacology, Division of Medical Sciences, National Cancer Centre, National University Hospital, Singapore
    Pharmacogenet Genomics 16:683-91. 2006
    ..To investigate the pharmacogenetic effect of SLCO1B1 *1a, *1b, *5 and *15 polymorphisms on irinotecan disposition in Asian cancer patients...
  59. pmc Elimination half-lives of polychlorinated biphenyl congeners in children
    Philippe Grandjean
    Institute of Public Health, University of Southern Denmark, Winsløwparken 17, DK 5000 Odense, Denmark
    Environ Sci Technol 42:6991-6. 2008
    ..The longest half-lives correspond to elimination of the parent PCB solely with a daily fat excretion rate of 1-2 g, whereas shorter half-lives assume metabolic break-down...
  60. ncbi Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling
    M Marderosian
    Department of Research and Development, Greater Los Angeles Veterans Affairs Healthcare System, Sepulveda, CA 91343, USA
    Oncogene 25:6277-90. 2006
    ....
  61. ncbi The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A
    A J Vlot
    The Van Creveldkliniek, and the Department of Haematology, Graduate School of Biomembranes, University Medical Center Utrecht, The Netherlands
    Thromb Haemost 83:65-9. 2000
    ..It is possible that these anti-A antibodies interact with endogenous vWF, thus affecting the half-life time of the factor VIII/vWF complex...
  62. pmc The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms
    Selma Sahin
    Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143 0912, USA
    Pharm Res 25:2869-77. 2008
    ..The t (1/2, op) is compared with previously proposed half-lives for predicting accumulation...
  63. pmc Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells
    Hemant Sarin
    National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Transl Med 6:80. 2008
    ..Using functionalized polyamidoamine dendrimer generations 1 through 8, we investigated how nanoparticle size influences particle accumulation within malignant glioma cells...
  64. ncbi An adaptable internal dose model for risk assessment of dietary and soil dioxin exposures in young children
    Brent D Kerger
    Health Science Resource Integration, Tallahassee, Florida 32309, USA
    Toxicol Sci 100:224-37. 2007
    ....
  65. ncbi Refinements on the age-dependent half-life model for estimating child body burdens of polychlorodibenzodioxins and dibenzofurans
    Brent D Kerger
    Health Science Resource Integration, 2976 Wellington Circle West, Tallahassee, FL 32309, USA
    Chemosphere 67:S272-8. 2007
    ....
  66. ncbi Naive and memory CD4+ T cell survival controlled by clonal abundance
    Jason Hataye
    Department of Microbiology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Science 312:114-6. 2006
    ..The inverse relation between clonal frequency and survival suggests that intraclonal competition could help maintain an optimally diverse repertoire of T cells and an optimal environment for the generation of long-lived memory cells...
  67. ncbi Differences in pharmacokinetics between children and adults--II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling
    Dale Hattis
    Marsh Institute, 950 Main Street, Clark University, Worcester, MA 01610, USA
    Risk Anal 23:117-42. 2003
    ..These apparently distinct subpopulations would be expected to exhibit different disposition of xenobiotics, particularly those that are highly lipophilic and poorly metabolized...
  68. ncbi Some pharmacokinetic data for danofloxacin in healthy goats
    M Atef
    Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Egypt
    Vet Res Commun 25:367-77. 2001
    ..The systemic bioavailability after IM injection was 65.70% +/- 10.28% and the serum protein-bound fraction was 13.55 +/- 1.78%...
  69. pmc Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids
    F Shojaee Aliabadi
    Department of Veterinary Basic Sciences, The Royal Veterinary College, Hawkshead Campus, North Mymms, Hatfield, Hertfordshire AL9 7TA, United Kingdom
    Antimicrob Agents Chemother 47:626-35. 2003
    ..8, 20.2, and 28.7 h, and slightly higher values were obtained for transudate and exudate. It is proposed that use of these data might provide a novel approach to the rational design of dosage schedules...
  70. ncbi Clinical pharmacokinetics of norfloxacin-glycine acetate after intravenous and intramuscular administration to horses
    S C Park
    Veterinary Pharmacology and Toxicology Labs, College of Veterinary Medicine, Kyungpook National University, 702 701 Sangyeok dong, Buk Gu, Daegu, Republic of Korea
    Res Vet Sci 74:79-83. 2003
    ..36 and 7.35 mgkg(-1) for i.m. and i.v. administration, respectively...
  71. pmc Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies
    D M Lane
    Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, UK
    Br J Cancer 70:521-5. 1994
    ..F(ab')2 fragments may provide a substantially enhanced method of delivering RIT...
  72. ncbi Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin
    Jetske M Meerum Terwogt
    The Netherlands Cancer Institute Slotervaart Hospital, Department of Pharmacy and Pharmacology, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 49:201-10. 2002
    ..To investigate the safety and pharmacokinetics of a new liposomal formulation of cisplatin, SPI-77, in patients with advanced malignancies...
  73. ncbi Blood-brain barrier equilibration of codeine in rats studied with microdialysis
    R Xie
    Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Sweden
    Pharm Res 15:570-5. 1998
    ..The purpose of the study was to investigate the distribution of codeine across the blood-brain barrier (BBB) in rats by microdialysis (MD)...
  74. pmc Blood-brain barrier transport of morphine in patients with severe brain trauma
    Per Ederoth
    Department of Anaesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden
    Br J Clin Pharmacol 57:427-35. 2004
    ..It was hypothesized in this clinical study that active efflux of morphine occurs also in human brain, and that brain injury would alter cerebral morphine pharmacokinetics...
  75. ncbi PKC-zeta-associated CK2 participates in the turnover of free IkappaBalpha
    G D Bren
    Department of Immunology, Mayo Clinic, Rochester, MN 55905, USA
    J Mol Biol 297:1245-58. 2000
    ..These studies demonstrate that the association between CK2 and PKC-zeta may play a major role in the control of the basal turnover of free IkappaBalpha, in the absence of extracellular stimuli...
  76. ncbi Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 64:1231-61. 2004
    ..Valdecoxib provides a valuable alternative in the treatment of chronic arthritis pain and acute pain...
  77. pmc Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    Y Tokuda
    Department of Surgery, Tokai University School of Medicine, Isehara, Kanagawa, Japan
    Br J Cancer 81:1419-25. 1999
    ..Further evaluation of this agent with 2-4 mg kg(-1) weekly intravenous infusion is warranted...
  78. pmc Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats--pharmacokinetic/pharmacodynamic modelling
    M R Bouw
    Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Faculty of Pharmacy, Uppsala University, Box 591, S-751 24, Uppsala, Sweden
    Br J Pharmacol 134:1796-804. 2001
    ..Half the effect delay of M6G can be explained by transport across the BBB, suggesting that the remaining effect delay of 53 min is a result of drug distribution within the brain tissue or rate-limiting mechanisms at the receptor level...
  79. pmc Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo
    C L Harris
    Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff, UK
    Clin Exp Immunol 129:198-207. 2002
    ..The data demonstrate the potential of CRP-Ig as reagents for sustained therapy of inflammatory disorders, including arthritis, but emphasize the need for careful design of fusion proteins to retain function...
  80. ncbi Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP)
    Eva H N Olsen
    Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, USA
    Blood 102:436-41. 2003
    ..Treatment with rhIL-11 with or without DDAVP may provide an alternative to plasma-derived products for some VWD and hemophilia A patients if it is shown safe in clinical trials...
  81. ncbi Severe 2,3,7,8-tetrachlorodibenzo- p-dioxin (TCDD) intoxication: kinetics and trials to enhance elimination in two patients
    Alexandra Geusau
    Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, University of Vienna, Medical School, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Arch Toxicol 76:316-25. 2002
    ..When employed twice a week, the amount of TCDD excreted by this method was comparable to fecal excretion. In view of costs and time involved, LDL-apheresis does not seem to be justified for enhancement of TCDD elimination...
  82. ncbi The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation
    D F Emerich
    Alkermes, Inc, Cambridge, Massachusetts, USA
    Clin Pharmacokinet 40:105-23. 2001
    ....
  83. ncbi The cap-to-tail guide to mRNA turnover
    C J Wilusz
    Department of Molecular Genetics and Microbiology, Robert Wood Johnson Medical School UMDNJ, Piscataway, New Jersey 08854, USA
    Nat Rev Mol Cell Biol 2:237-46. 2001
    ..But what are the sequence elements and factors that control the half-lives of mRNAs?..
  84. ncbi Genome-wide survey of mRNA half-lives in Bacillus subtilis identifies extremely stable mRNAs
    G Hambraeus
    Department of Cell and Organism Biology, Lund University, Sölvegatan 35, 223 62 Lund, Sweden
    Mol Genet Genomics 269:706-14. 2003
    ..The identified set of extremely stable mRNAs may be useful in the construction of stable recombinant genes for the overproduction of biomolecules in Bacillus species...
  85. ncbi The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics
    M Hammarlund-Udenaes
    Division of Biopharmaceutics and Pharmacokinetics, Department of Pharmacy, Uppsala University, Box 580, SE 751 23, Uppsala, Sweden
    Adv Drug Deliv Rev 45:283-94. 2000
    ..The half-life in brain ECF vs. the half-life in blood gives information on rate-limiting steps in drug delivery and elimination from the CNS. Examples are given on microdialysis studies of analgesic and antiepileptic drugs...
  86. ncbi Lack of bioequivalence between two aciclovir tablets in healthy subjects
    Hossein Amini
    Department of Physiology and Pharmacology, Cardiovascular Research Center, Golestan University of Medical Sciences, Gorgan, Iran
    Clin Drug Investig 28:47-53. 2008
    ..This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovirax (reference), in 12 healthy volunteers...
  87. ncbi The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
    Yan ling He
    Exploratory Development, Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts 02139, USA
    Clin Pharmacokinet 46:787-802. 2007
    ..The objective of this study was to assess the absolute oral bioavailability of vildagliptin by comparing the systemic exposure after oral and intravenous administration in healthy volunteers...
  88. ncbi Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial
    A Portoles
    Clinical Pharmacology Studies Unit, Clinical Pharmacology Service, Hospital Clinico San Carlos, Madrid, Spain
    J Clin Pharmacol 46:1195-203. 2006
    ..Coadministration of either omeprazole or lansoprazole did not significantly affect the pharmacokinetics of a single dose of ivabradine. No pharmacodynamic interaction or safety concerns were evidenced...
  89. ncbi Pharmacokinetics and bioequivalence evaluation of two gabapentin preparations after a single oral dose in healthy Korean volunteers
    H Y Cho
    College of Pharmacy and Institute of Bioequivalence and Hospital Bridging Study, CNUH, Chonnam National University, Gwangju, Korea
    Int J Clin Pharmacol Ther 44:386-92. 2006
    ..To evaluate the bioequivalence of a single oral 400 mg dose of 2 gabapentin preparations in healthy male Korean volunteers...
  90. ncbi Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium
    W Arns
    Kliniken der Stadt Köln gGmbH, Clinic Merheim, Medical Clinic I, Cologne, Germany
    Int J Clin Pharmacol Ther 44:375-85. 2006
    ..Enteric-coated mycophenolate sodium is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying MPA release until the small intestine...
  91. ncbi Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats
    Dong Hyun Choi
    College of Medicine, Chosun University, 375 Seosuk dong, Dong Gu, Gwangju, Korea
    Biopharm Drug Dispos 29:45-50. 2008
    ....
  92. ncbi The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers
    Helen S Pentikis
    ICON Development Solutions, Ellicott City, Maryland, USA
    Pharmacotherapy 27:1361-9. 2007
    ..To evaluate the potential of rifaximin, an oral nonabsorbed (< 0.4%) structural analog of rifampin, to induce human hepatic and/or intestinal cytochrome P450 (CYP) 3A enzymes, with use of a known CYP3A probe, midazolam...
  93. ncbi HPLC method for the pharmacokinetics and tissue distribution of taspine solution and taspine liposome after intravenous administrations to mice
    Wen Lu
    School of Medicine, Xi an Jiaotong University, Xi an 710061, PR China
    J Pharm Biomed Anal 46:170-6. 2008
    ..It can thus be concluded that incorporation into liposomes prolonged taspine retention within the systemic circulation, increased its distribution to the spleen and liver but reduced its distribution to the heart and brain...
  94. ncbi Stereoselective quantification of methadone and a d(6)-labeled isotopomer using high performance liquid chromatography-atmospheric pressure chemical ionization mass-spectrometry: application to a pharmacokinetic study in a methadone maintained subject
    David J R Foster
    Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide 5005, Australia
    Ther Drug Monit 28:559-67. 2006
    ....
  95. ncbi Oral bioavailability, tissue distribution and depletion of flumequine in the food producing animal, chicken for fattening
    A Anadon
    Department of Toxicology and Pharmacology, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain
    Food Chem Toxicol 46:662-70. 2008
    ..Flumequine administered at a dosage of 24 mg/kg bw every 24h for 5 days, with a withdrawal time of 2d ays, resulted in flumequine concentrations in target tissues that were less than the European Union maximal residue limits...
  96. ncbi A comparative study of the pharmacokinetics of ibuprofen arginate versus dexibuprofen in healthy volunteers
    Belen Sadaba
    Clinical Research Unit, Clinica Universitaria de Navarra, Universidad de Navarra, 31008, Pamplona, Spain
    Eur J Clin Pharmacol 62:849-54. 2006
    ..The primary objective of this study was to compare the 12-h pharmacokinetic profile of S(+)-ibuprofen following administration of single doses of ibuprofen arginate (600 mg) and dexibuprofen (400 mg) in healthy volunteers...
  97. ncbi Pharmacokinetics of astragaloside iv in beagle dogs
    Qi Zhang
    College of Life Science and Pharmacy, Nanjing University of Technology, Nanjing, People s Republic of China
    Eur J Drug Metab Pharmacokinet 32:75-9. 2007
    ..4%. The plasma protein binding rate of AGS-IV was about 90% within a concentration range of 250-1000 ng.ml(-1). There was no significant species difference regarding the pharmacokinetics of AGS-IV between the rat and the Beagle dog...
  98. ncbi In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs
    Minoli A Perera
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, 500 West 12th Ave, Columbus, OH 43210, USA
    Drug Metab Dispos 34:1713-21. 2006
    ..These studies demonstrate that S-4 maintains its promising pharmacokinetic properties in dogs (i.e., high oral bioavailability and linear kinetics) and is largely eliminated via hepatic metabolism by both phase I and phase II enzymes...
  99. ncbi Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus)
    M S Kim
    Division of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University, Daejeon, Korea
    J Vet Pharmacol Ther 29:397-402. 2006
    ..25 h, with the C(max) of 0.03 +/- 0.01 microg/mL at 6.67 +/- 2.31 h. Ciprofloxacin was eliminated with terminal half-life t(1/2,beta) of 52.08 +/- 17.34 h for intravenous administration and 52.43 +/- 22.37 h for oral administration...
  100. ncbi HPLC study of pharmacokinetics and tissue distribution of morroniside in rats
    Xiaona Li
    Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang 050017, PR China
    J Pharm Biomed Anal 45:349-55. 2007
    ..It was also found there was no long-term accumulation of morroniside in rat tissues...
  101. doi Evaluation of the interaction between ivermectin and albendazole following their combined use in lambs
    L Alvarez
    Laboratorio de Farmacologia, Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires UNCPBA, Campus Universitario, Tandil, Argentina
    J Vet Pharmacol Ther 31:230-9. 2008
    ..This type of pharmacology-based evaluation of drug interactions is becoming highly relevant as drug combinations are now widely used as an alternative to control resistant helminth parasites in livestock...

Research Grants89

  1. Transscleral Transport & Polymeric Delivery of Antibody & Steroids for Macular Ed
    Ashim Mitra; Fiscal Year: 2009
    ..Risk of drug precipitation due to poor solubility;and short vitreal half life upon intravitreal injection are the key deterrents in their delivery...
  2. Safety and PK Study in Hepatic Impairment Patients
    Weizhong Cai; Fiscal Year: 2009
    ..Successful completion of the proposed studies will enable us to evaluate the efficacy and safety of BB3 in larger Phase IIB studies in liver fibrosis or acute liver injury. ..
  3. Safety and PK Study in Hepatic Impairment Patients
    Weizhong Cai; Fiscal Year: 2010
    ..Successful completion of the proposed studies will enable us to evaluate the efficacy and safety of BB3 in larger Phase IIB studies in liver fibrosis or acute liver injury. ..
  4. Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
    VINCENT COLLINS OFUKA NJAR; Fiscal Year: 2010
    ..We strongly believe that the proposed studies will fulfill the requirements for advanced preclinical studies with 1-2 candidates in view of Phase 1 study in breast cancer patients. ..
  5. Long-acting Growth Hormone for Treating HIV-Associated Adipose Redistribution Syn
    George Cox; Fiscal Year: 2009
    ....
  6. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert M Weiss; Fiscal Year: 2010
    ..Our first test of these nanoparticles will use a mouse model of bladder cancer. Thus, we can determine the therapeutic potential of siRNA for treatment of urologic diseases. ..
  7. Targeted siRNA nanotechnology for intravesical treatment of urologicaldiseases
    Robert Weiss; Fiscal Year: 2009
    ..Our first test of these nanoparticles will use a mouse model of bladder cancer. Thus, we can determine the therapeutic potential of siRNA for treatment of urologic diseases. ..
  8. Transscleral Transport & Polymeric Delivery of Antibody & Steroids for Macular Ed
    Ashim K Mitra; Fiscal Year: 2010
    ..Risk of drug precipitation due to poor solubility;and short vitreal half life upon intravitreal injection are the key deterrents in their delivery...
  9. FILGRASTIM SD/01 IN NONSMALL CELL LUNG CANCER
    Jeffrey Crawford; Fiscal Year: 1999
    ..A manuscript is in progress. SIGNIFICANCE: This study may contribute to an improved form of therapy for chemotherapy induced neutropenia. The future plans will depend on the results of this trial. ..
  10. The Role of Carboxypeptidase B and its Substrates in Rheumatoid Arthritis
    William H Robinson; Fiscal Year: 2010
    ..The proposed experiments will provide insights into pathogenesis, and could lead to development of new therapeutic approaches for RA. ..
  11. Associations between Non-8-Carbon-Chain Perfuoroalkyl Acids and Serum Lipid, Live
    Stephanie J Frisbee; Fiscal Year: 2010
    ....
  12. EFFECT OF DIETARY FACTORS ON METALLOTHIONEIN LEVELS
    PHILIP WHANGER; Fiscal Year: 1980
    ..The low MW zinc binding ligand from kidney and the copper and zinc containing proteins from choroid plexus are planned to be purified by gel filtration and ion exchange resins and characterized...
  13. Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder
    CHARLES PIERCE; Fiscal Year: 2009
    ..This Phase 1 SBIR proposal will determine the safety, tolerability, and pharmacokinetics of higher doses of betahistine and characterize dose-response for improving attention and impulsivity in young adults with ADHD. ..
  14. ANTIGEN RECOGNITION BY LYMPHOCYTES
    Philippa Marrack; Fiscal Year: 2009
    ..lymphocytes survive for a while as anergic cells and do not respond productively to antigen and have a shortened half life. The Projects in this Program will examine the ways in which lymphocytes are controlled, comparing the ..
  15. ANTIGEN RECOGNITION BY LYMPHOCYTES
    Philippa Marrack; Fiscal Year: 2009
    ..lymphocytes survive for a while as anergic cells and do not respond productively to antigen and have a shortened half life. The Projects in this Program will examine the ways in which lymphocytes are controlled, comparing the ..
  16. ANTIGEN RECOGNITION BY LYMPHOCYTES
    Philippa Marrack; Fiscal Year: 2007
    ..lymphocytes survive for a while as anergic cells and do not respond productively to antigen and have a shortened half life. The Projects in this Program will examine the ways in which lymphocytes are controlled, comparing the ..
  17. ROLE OF S-ADENOSYLMETHIONINE ON UBC9 AND SUMOYLATION IN LIVER CANCER AND ALCOHOLI
    Maria Lauda Tomasi; Fiscal Year: 2010
    ....
  18. Resolution of Epithelial Cell Hyperplasia
    Yohannes Tesfaigzi; Fiscal Year: 2009
    ..Reducing epithelial cell hyperplasia may also help reduce the risk of developing lung cancer. ..
  19. Resolution of Epithelial Cell Hyperplasia
    Yohannes Tesfaigzi; Fiscal Year: 2010
    ..Reducing epithelial cell hyperplasia may also help reduce the risk of developing lung cancer. ..
  20. Optimization of SWCNT/siRNA complex formulation for tumor accumulation
    Lynn Kirkpatrick; Fiscal Year: 2012
    ..These critical studies will move this novel technology one step closer to full pre-clinical development and eventually to a clinical trial study. ..
  21. Pilot Clinical Study in Renal Transplantation
    Weizhong Cai; Fiscal Year: 2009
    ..therapies, are limited by immune- mediated responses, cost-prohibitive production schemes and relatively short-half life of the protein in vivo...
  22. Serum IGFs--Effects of a Soy Intervention in Humans
    Johanna Lampe; Fiscal Year: 2002
    ..It provides an ideal design to evaluate the effects of isoflavones on the IGF system and to explore relationships between IGFs and colonic epithelial cell proliferation in humans. ..
  23. Serum IGFs--Effects of a Soy Intervention in Humans
    Johanna Lampe; Fiscal Year: 2001
    ..It provides an ideal design to evaluate the effects of isoflavones on the IGF system and to explore relationships between IGFs and colonic epithelial cell proliferation in humans. ..
  24. Pharmacogenetics of ACE inhibitor-associated angioedema
    NANCY JOAN BROWN; Fiscal Year: 2011
    ..Understanding how ACE inhibitors and DPPIV inhibitors interact will help physicians prescribe these medications safely and will influence the development of new medications to treat diabetes and high blood pressure. ..
  25. Pharmacogenetics of ACE inhibitor-associated angioedema
    NANCY JOAN BROWN; Fiscal Year: 2010
    ..Understanding how ACE inhibitors and DPPIV inhibitors interact will help physicians prescribe these medications safely and will influence the development of new medications to treat diabetes and high blood pressure. ..
  26. Enzyme therapy for hyperhomocysteinemia
    Yuying Tan; Fiscal Year: 2005
    ..Phase II results will lead to an IND for MEGC-PEG-rMETase for end stage renal disease patients and other patients with intractable hyperhomocysteinemia and high cardiovascular disease mortality. ..
  27. Gene Therapy for hemophilia using muscle-expressed FVIIa
    Katherine A High; Fiscal Year: 2011
    ..The proposed work will allow us to increase the therapeutic applicability of our approach and enhance its safety, prior to a clinical application. ..
  28. Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta
    James F Kronauge; Fiscal Year: 2010
    ..The short physical half life of the Iodine-123 (13 hours) necessitates GMP production for each study and preliminary studies are only ..
  29. Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta
    JAMES KRONAUGE; Fiscal Year: 2009
    ..The short physical half life of the Iodine-123 (13 hours) necessitates GMP production for each study and preliminary studies are only ..
  30. Development of Small Heat Shock Proteins as Therapeutic Agents in the Eye
    JONATHAN MARK PETRASH; Fiscal Year: 2010
    ..Our proposed studies could substantially improve the quality of life of affected patients by preventing vision loss and associated financial burdens due to lost productivity and increased medical expenses. ..
  31. Development of Small Heat Shock Proteins as Therapeutic Agents in the Eye
    JONATHAN PETRASH; Fiscal Year: 2009
    ..Our proposed studies could substantially improve the quality of life of affected patients by preventing vision loss and associated financial burdens due to lost productivity and increased medical expenses. ..
  32. Humanizing N-linked glycosylation in Escherichia coli
    ADAM FISHER; Fiscal Year: 2009
    ..Therefore, the focus of these studies is the development of "glyco-engineered" bacteria that are capable of producing authentic human glycoproteins. ..
  33. Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing
    George Cox; Fiscal Year: 2009
    ..This protein may provide Multiple Sclerosis patients with a more effective and more convenient therapy for the treatment their disease. ..
  34. SYNTHESIS AND ASSEMBLY OF FLAGELLAR PROTEINS
    Joel Rosenbaum; Fiscal Year: 1990
    ..The flagellar dynein-ATPase is prefabricated in the cytoplasm during flagellar regeneration and we will use dynein mutants to describe the steps in the assembly of the dynein polypeptides...
  35. GM-CSF analogs for treating acute radiation syndrome
    George Cox; Fiscal Year: 2009
    ..Our long-acting GM-CSF analog may prove useful for improving survival in people exposed to an otherwise lethal dose of radiation as a result of a radiological/nuclear disaster. ..
  36. GM-CSF analogs for treating acute radiation syndrome
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..Our long-acting GM-CSF analog may prove useful for improving survival in people exposed to an otherwise lethal dose of radiation as a result of a radiological/nuclear disaster. ..
  37. MAPK-activated protein kinase 2 regulation of endothelial cell migration
    Shuang Huang; Fiscal Year: 2009
    ..We also wish to employ the knowledge obtained from these studies to develop a therapeutic approach for inhibiting pathological angiogenesis. ..
  38. MAPK-activated protein kinase 2 regulation of endothelial cell migration
    Shuang Huang; Fiscal Year: 2010
    ..We also wish to employ the knowledge obtained from these studies to develop a therapeutic approach for inhibiting pathological angiogenesis. ..
  39. Mesenchymal Stem Cells as Drug Delivery Vehicles in CML
    Michael Andreeff; Fiscal Year: 2003
    ..In conclusion, we propose to develop MSC as a platform for the in situ production of therapeutic proteins in CML. ..
  40. Sustained Release Depot Olanzapine
    Thomas J Smith; Fiscal Year: 2010
    ..We plan to repeat this strategy in the development of these important treatments for schizophrenia and manic-depressive illness. ..
  41. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2012
    ..This new drug then goes one step further: it will improve the quality of life for cancer patients, their caregivers and families by providing a significantly more effective and less painful therapy than is currently available. ..
  42. Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
    Paul J Shami; Fiscal Year: 2010
    ..This new drug then goes one step further: it will improve the quality of life for cancer patients, their caregivers and families by providing a significantly more effective and less painful therapy than is currently available. ..
  43. Stem cells for novel gene delivery of nitric oxide in the gut
    Hiroshi Mashimo; Fiscal Year: 2009
    ....
  44. Human Zinc Transporter Zip 13 and Cellular Zinc Homeostasis
    Joel Walker; Fiscal Year: 2007
    ..This proposal will begin to identify the genetic mechanisms controlling human Zip13 in response to low cellular zinc providing clues to how human cells regulate zinc metabolism. [unreadable] [unreadable] [unreadable]..
  45. APPLICATIONS OF PHARMACOKINETICS IN CLINICAL PSYCHIATRY
    Richard Shader; Fiscal Year: 1992
    ..Plasma levels and clinical effects of the study drugs are monitored during the treatment period and the withdrawal phase...
  46. APPLICATIONS OF PHARMACOKINETICS IN CLINICAL PSYCHIATRY
    Richard Shader; Fiscal Year: 1990
    ..Plasma levels and clinical effects of the study drugs are monitored during the treatment period and the withdrawal phase...
  47. Regulation of the Endocytic Trafficking of CFTR
    Agnieszka Swiatecka Urban; Fiscal Year: 2009
    ..The long-term goal of this application is to develop a drug that will restore salt movement into and out of cells and alleviate the symptoms in CF patients. ..
  48. Regulation of the Endocytic Trafficking of CFTR
    Agnieszka Swiatecka Urban; Fiscal Year: 2010
    ..The long-term goal of this application is to develop a drug that will restore salt movement into and out of cells and alleviate the symptoms in CF patients. ..
  49. Regulation of the Endocytic Trafficking of CFTR
    Agnieszka Swiatecka Urban; Fiscal Year: 2009
    ..The long-term goal of this application is to develop a drug that will restore salt movement into and out of cells and alleviate the symptoms in CF patients. ..
  50. Nanocarrier formulated enzyme for the treatment of S. aureus infection
    GERARDO M CASTILLO; Fiscal Year: 2012
    ..coli expressing lyso) that will be used for: 1) this project to supply our lyso needs, and 2) as reference cells for the planned post-SBIR IND filing and clinical trial. PharmaIN Corp. Confidential ..
  51. Glycine rich sequences with pharmacokinetic enhancing properties of PEG polymers
    Volker Schellenberger; Fiscal Year: 2009
    ..These rPEGs can be directly fused to protein pharmaceuticals to increase their serum half-life. We will validate rPEG technology by developing a long-acting version of human growth hormone for the treatment of dwarfism in children. ..
  52. TNP-470 120 Hour Continuous Infusion in Advanced Cancer
    John Marshall; Fiscal Year: 2000
    ..In addition, the short half life that we have seen of the parent compound in human pharmacokinetic studies would support a continuous infusion ..
  53. COCAINE, ALCOHOL, AND COCAETHYLENE--CLINICAL EFFECTS
    Elinore McCance Katz; Fiscal Year: 2000
    ..In total, these studies should provide significant contributions to the current state of knowledge regarding the epidemiology of cocaine-alcohol abuse and treatment of these disorders. ..
  54. COCAINE, ALCOHOL, AND COCAETHYLENE--CLINICAL EFFECTS
    Elinore McCance Katz; Fiscal Year: 2002
    ..In total, these studies should provide significant contributions to the current state of knowledge regarding the epidemiology of cocaine-alcohol abuse and treatment of these disorders. ..
  55. COCAINE, ALCOHOL, AND COCAETHYLENE--CLINICAL EFFECTS
    Elinore McCance Katz; Fiscal Year: 2002
    ..In total, these studies should provide significant contributions to the current state of knowledge regarding the epidemiology of cocaine-alcohol abuse and treatment of these disorders. ..
  56. COCAINE, ALCOHOL, AND COCAETHYLENE--CLINICAL EFFECTS
    Elinore McCance Katz; Fiscal Year: 2001
    ..In total, these studies should provide significant contributions to the current state of knowledge regarding the epidemiology of cocaine-alcohol abuse and treatment of these disorders. ..
  57. Crystalline Antiproliferative Drugs for Intraocular Diseases
    William R Freeman; Fiscal Year: 2010
    ..the optimal structural and formulation variables to provide for a high therapeutic index and long intraocular half life. The best compounds and formulations will be tested in accepted animal models of the important retinal diseases ..
  58. HORMONAL REGULATION OF MESSENGER RNA STABILITY
    Daniel R Schoenberg; Fiscal Year: 2010
    ..This research seeks to identify the components of the PMR1 decay complex, identify the scope of PMR1-mediated decay and relate both of these to the invasive growth of cancer cells. ..
  59. Crystalline Antiproliferative Drugs for Intraocular Diseases
    William Freeman; Fiscal Year: 2009
    ..the optimal structural and formulation variables to provide for a high therapeutic index and long intraocular half life. The best compounds and formulations will be tested in accepted animal models of the important retinal diseases ..
  60. Clinical Trial of Ceftriaxone in ALS
    Merit Cudkowicz; Fiscal Year: 2006
    ..Secondary outcome measures will include ALSFRS-R, vital capacity, strength, and the long-term safety and tolerability of ceftriaxone in this population. ..
  61. Clinical Trial of Ceftriaxone in ALS
    Merit Cudkowicz; Fiscal Year: 2007
    ..Secondary outcome measures will include ALSFRS-R, vital capacity, strength, and the long-term safety and tolerability of ceftriaxone in this population. ..
  62. Clinical Trial of Ceftriaxone in ALS
    Merit Cudkowicz; Fiscal Year: 2007
    ..Secondary outcome measures will include ALSFRS-R, vital capacity, strength, and the long-term safety and tolerability of ceftriaxone in this population. ..
  63. Clinical Trial of Ceftriaxone in ALS
    Merit Cudkowicz; Fiscal Year: 2007
    ..Secondary outcome measures will include ALSFRS-R, vital capacity, strength, and the long-term safety and tolerability of ceftriaxone in this population. ..
  64. Clinical Trial of Ceftriaxone in ALS
    Merit Cudkowicz; Fiscal Year: 2007
    ..Secondary outcome measures will include ALSFRS-R, vital capacity, strength, and the long-term safety and tolerability of ceftriaxone in this population. ..
  65. Clinical Trial of Ceftriaxone in ALS
    Merit Cudkowicz; Fiscal Year: 2009
    ..Secondary outcome measures will include ALSFRS-R, vital capacity, strength, and the long-term safety and tolerability of ceftriaxone in this population. ..
  66. Clinical Trial of Ceftriaxone in ALS
    Merit Cudkowicz; Fiscal Year: 2004
    ..Secondary outcome measures will include ALSFRS-R, vital capacity, strength, and the long-term safety and tolerability of ceftriaxone in this population. ..
  67. Long-Acting G-CSF analogs for treating acute radiation syndrome
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..Our long-acting G-CSF analog may prove useful for improving survival in people exposed to an otherwise lethal dose of radiation as a result of a radiological/nuclear disaster. ..
  68. Long-Acting IL-11 Analog for Treating Acute Radiation Syndrome
    GEORGE NORBERT COX; Fiscal Year: 2010
    ..Our long-acting IL-11 analog may prove useful for improving survival in people exposed to an otherwise lethal dose of radiation as a result of a radiological/nuclear disaster. ..
  69. Long-Acting G-CSF analogs for treating acute radiation syndrome
    George Cox; Fiscal Year: 2009
    ..Our long-acting G-CSF analog may prove useful for improving survival in people exposed to an otherwise lethal dose of radiation as a result of a radiological/nuclear disaster. ..
  70. PHARMACOKINETIC STUDIES OF DIGITALIS GLYCOSIDES
    DONALD PERRIER; Fiscal Year: 1980
    ....
  71. Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs
    VENKATA REDDY; Fiscal Year: 2009
    ..abstract_text> ..
  72. Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
    Frank Anania; Fiscal Year: 2009
    ..This proposal meets the goals of the US Public Health Service in treating chronic liver diseases. ..
  73. Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs
    Venkata M Reddy; Fiscal Year: 2010
    ..abstract_text> ..
  74. Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
    Frank Anania; Fiscal Year: 2007
    ..This proposal meets the goals of the US Public Health Service in treating chronic liver diseases. ..
  75. Potential Mechanisms of Glucagon-like peptide-1 in Fatty Liver Disease
    Frank A Anania; Fiscal Year: 2010
    ..This proposal meets the goals of the US Public Health Service in treating chronic liver diseases. ..
  76. Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs
    VENKATA REDDY; Fiscal Year: 2009
    ..abstract_text> ..
  77. INTESTINAL TRANSCYTOSIS OF IGG IN ADULT LIFE
    Richard Blumberg; Fiscal Year: 2009
    ..This raises the possibility that blockade of FcRn function may be of therapeutic utility in colitis if our studies support an involvement of FcRn in inflammation. ..
  78. INTESTINAL TRANSCYTOSIS OF IGG IN ADULT LIFE
    Richard Blumberg; Fiscal Year: 2007
    ..This raises the possibility that blockade of FcRn function may be of therapeutic utility in colitis if our studies support an involvement of FcRn in inflammation. ..
  79. EFFECTS OF 2,3,7,8-TCDD ON ESTROGENIC RESPONSES
    Stephen Safe; Fiscal Year: 1993
    ..The results of this study will not only enhance our understanding of the interaction between two or more endocrine systems but also identify induced proteins which may have some clinical prognostic value for breast cancer in women...
  80. LEUKOTRIENES AND SLOW REACTING SUBSTANCE OF ANAPHYLAXIS
    Robert Murphy; Fiscal Year: 2003
    ..The development of a quantitative assay for such a metabolite will have a major impact on the assessment of LTB4 production in human health as well as disease. ..
  81. LEUKOTRIENES AND SLOW REACTING SUBSTANCE OF ANAPHYLAXIS
    Robert Murphy; Fiscal Year: 2005
    ..The development of a quantitative assay for such a metabolite will have a major impact on the assessment of LTB4 production in human health as well as disease. ..
  82. LEUKOTRIENES AND SLOW REACTING SUBSTANCE OF ANAPHYLAXIS
    Robert Murphy; Fiscal Year: 2004
    ..The development of a quantitative assay for such a metabolite will have a major impact on the assessment of LTB4 production in human health as well as disease. ..
  83. LEUKOTRIENES AND SLOW REACTING SUBSTANCE OF ANAPHYLAXIS
    Robert Murphy; Fiscal Year: 2002
    ..The development of a quantitative assay for such a metabolite will have a major impact on the assessment of LTB4 production in human health as well as disease. ..
  84. Engineering enzymes for anti-tumor suicide gene therapy
    Barry Stoddard; Fiscal Year: 2007
    ..Our hypothesis is that decitabine should ultimately couple with engineered enzyme variants to yield improvements in the performance of dCK, due to the lack of this activity in non-cancerous tissues. ..
  85. Engineering enzymes for anti-tumor suicide gene therapy
    Barry Stoddard; Fiscal Year: 2009
    ..Our hypothesis is that decitabine should ultimately couple with engineered enzyme variants to yield improvements in the performance of dCK, due to the lack of this activity in non-cancerous tissues. ..
  86. Renal Senescence and Transplantation
    Bryan Myers; Fiscal Year: 2007
    ..abstract_text> ..